Novo Nordisk A/S
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
Efficacy and Safety of Metformin and Liraglutide in Obese Subjects With Type 2 Diabetes Previously Treated With an Oral Hypoglycemic Agent
Phase 2
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2012-01-18
- Last Posted Date
- 2017-01-26
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 223
- Registration Number
- NCT01511198
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Charleston, West Virginia, United States
Effect of Liraglutide on the Beta-cell Responsiveness in Subjects With Type 2 Diabetes Compared to a Healthy Control Group
Phase 1
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- Drug: placebo
- First Posted Date
- 2012-01-18
- Last Posted Date
- 2017-01-26
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 20
- Registration Number
- NCT01511185
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Ann Arbor, Michigan, United States
Effect of Liraglutide as add-on to Metformin Compared to Either Liraglutide or Metformin Alone, or to a Combination of Metformin and a SU (Sulphonylurea) Agent in Subjects With Type 2 Diabetes
Phase 2
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2012-01-18
- Last Posted Date
- 2017-01-25
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 145
- Registration Number
- NCT01511172
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Yaxley. Peterborough, United Kingdom
An Active Surveillance Program for Cases of Medullary Thyroid Carcinoma (MTC)
- Conditions
- DiabetesDiabetes Mellitus, Type 2Weight ManagementMedullary Thyroid Carcinoma
- Interventions
- Other: No treatment given
- First Posted Date
- 2012-01-18
- Last Posted Date
- 2023-06-13
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 6750
- Registration Number
- NCT01511393
- Locations
- 🇺🇸
United BioSource, LLC, Morgantown, West Virginia, United States
Comparison of Liraglutide Inhaled Into the Lungs Compared to Liraglutide Injected Under the Skin in Healthy Male Volunteers
Phase 1
Completed
- Conditions
- DiabetesHealthy
- Interventions
- First Posted Date
- 2012-01-18
- Last Posted Date
- 2015-03-26
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 32
- Registration Number
- NCT01511159
Effect of Liraglutide on Glucagon Secretion in Subjects With Type 2 Diabetes
Phase 1
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- Drug: placebo
- First Posted Date
- 2012-01-13
- Last Posted Date
- 2024-02-01
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 19
- Registration Number
- NCT01509742
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Bad Lauterberg, Germany
Comparison of Liraglutide and Glimepiride on Blood Sugar Control in Subjects With Type 2 Diabetes
Phase 2
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2012-01-13
- Last Posted Date
- 2017-01-24
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 196
- Registration Number
- NCT01509755
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Worksop, United Kingdom
Effect of Liraglutide on Glucose Profiles and Gastric Emptying in Subjects With Type 2 Diabetes
Phase 2
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- Drug: placebo
- First Posted Date
- 2012-01-12
- Last Posted Date
- 2017-01-24
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 17
- Registration Number
- NCT01508923
- Locations
- 🇩🇰
Novo Nordisk Investigational Site, Århus C, Denmark
Influence on the Effect of an Oral Contraceptive Drug After Administration of Liraglutide in Postmenopausal Women
Phase 1
Completed
- Conditions
- Diabetes Mellitus, Type 2Diabetes
- Interventions
- First Posted Date
- 2012-01-12
- Last Posted Date
- 2017-01-24
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 21
- Registration Number
- NCT01508858
- Locations
- 🇸🇪
Novo Nordisk Investigational Site, Uppsala, Sweden
Safety and Tolerability of Liraglutide in Subjects With Impaired Kidney Function and in Subjects With Normal Kidney Function
- First Posted Date
- 2012-01-12
- Last Posted Date
- 2017-01-24
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 30
- Registration Number
- NCT01508806
- Locations
- 🇦🇺
Novo Nordisk Investigational Site, Christchurch, Australia
© Copyright 2025. All Rights Reserved by MedPath